piRNA Biomarker Identification Service

Revealing the possibility of piRNAs serving as biomarkers has the potential to transform disease research and diagnostics. Protheragen's piRNA biomarker identification service offers a novel, highly efficient approach to identifying new biomarkers that possess diagnostic, prognostic, and therapeutic monitoring utility for various diseases.

Overview of piRNA Biomarker

PiRNAs are a category of small non-coding RNAs that are around 24-31 nucleotides long, which were first reported due to their interaction with PIWI proteins and activity in germ cells. Newer findings demonstrate that piRNAs not only have essential functions in the reproductive system but are also abundantly present in somatic cells, where they are involved in many biological activities. These features of piRNAs make them very valuable biomarkers, especially in disease diagnosis, prognosis assessment, and therapeutic response monitoring. The following are the most important advantages of piRNAs as biomarkers:

Disease-associated piRNA Biomarkers

piRNAs have shown great potential as biomarkers in cancer, neurodegenerative disorders, reproductive system diseases, metabolic disorders, and cardiovascular diseases. For example, specific piRNA expression profiles have been found in breast cancer, lung cancer, prostate cancer, gastric cancer, and Alzheimer's disease (AD), suggesting that they can serve as diagnostic biomarkers at an early stage. The table below shows some of the known disease-associated piRNA biomarkers identified to date.

Our Services

At Protheragen, we are dedicated to advancing the field of piRNA research and its applications in disease diagnosis, prognosis, and therapeutic monitoring. Our piRNA biomarker identification service aims to help researchers discover and validate piRNA biomarkers precisely and reliably. With state-of-the-art science and technology, bioinformatics, and a team of qualified scientists, we provide tailor-made and comprehensive solutions for your research needs.

Service Workflow

Sample Preparation

Extract total RNA or small RNA fragments from biological samples while ensuring the preservation of RNA integrity. Enforce strict quality control criteria to ensure the best starting material for subsequent analysis.

Bioinformatics Analysis

The sequencing or microarray data that was collected will be subjected to in-depth computational analysis. The appropriate bioinformatics tools and algorithms will be used for the identification of diagnostic or prognostic piRNA biomarkers.

High-Throughput Sequencing

Next-generation sequencing or microarray analysis is utilized in the thorough detection and quantification of piRNAs in samples, providing valuable information in the possible biomarker candidates based on their differential expression profiles.

Experimental Validation

Use qPCR, in situ hybridization, or other molecular detection for the validation of piRNA biomarker candidates. This validation procedure substantiates the unique expression of the selected piRNAs and their suitability as biomarkers.

Key Technologies and Methods

• High-Throughput Sequencing: Next-generation sequencing, microarray analysis, single-end sequencing, spike-in controls, qubit fluorometry, etc.
• Bioinformatics & Machine Learning: ROC curve analysis, survival analysis (Cox regression), machine learning algorithms (e.g., LASSO, Random Forest, SVM), etc.
• Experimental Validation: qRT-PCR, digital droplet PCR (ddPCR), Northern blotting, gene editing knockout, fluorescence in situ hybridization (FISH), single-cell sequencing, etc.

Multiple Disease Research

Our scientists identify piRNA biomarkers for a variety of diseases, including but not limited to the following:

Protheragen is committed to advancing piRNA biomarker research and providing cutting-edge services to help you realize the full potential of piRNAs in disease management. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.